Teresa Valero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Teresa Valero has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Asier Unciti-Broceta
Edinburgh Cancer Research Cancer Research UK Scotland Centre Institute of Genetics and Cancer University of Edinburgh Crewe Road South Edinburgh EH4 2XR UK
17 shared publications Alison F. Munro
8 shared publicationsBin-Zhi Qian
8 shared publicationsCarolin Temps
8 shared publications- Christina Schoenherr
Edinburgh Cancer Research Centre, University of Edinburgh, United Kingdom
8 shared publications Craig Fraser
8 shared publications
Latest Publications
- Open Access
- 16 April 2024
- Published by Wiley in Chemistry – A European Journal
- Vol. 30 (30) , e202400611
Development of Biocompatible Cu(I)‐Microdevices for Bioorthogonal Uncaging and Click Reactions
Transition‐metal‐catalyzed bioorthogonal reactions emerged a decade ago as a novel strategy to implement spatiotemporal control over enzymatic functions and pharmacological interventions. The use of this methodology in experimental therapy is driven by the ambition of improving the tolerability and PK properties of clinically‐used therapeutic agents. The preclinical potential of bioorthogonal catalysis has been validated in vitro and in vivo with the in situ generation of a broad range of drugs, including cytotoxic agents, anti‐inflammatory drugs and anxiolytics. In this article, we report our investigations towards the preparation of solid‐supported Cu(I)‐microdevices and their application in bioorthogonal uncaging and click reactions. A range of ligand‐functionalized polymeric devices and off‐on Cu(I)‐sensitive sensors were developed and tested under conditions compatible with life. Last, we present a preliminary exploration of their use for the synthesis of PROTACs through CuAAC assembly of two heterofunctional mating units.
- 16 April 2024
- Published by Wiley in Chemistry – A European Journal
- Vol. 30 (30) , e202400611
Open AccessDevelopment of Biocompatible Cu(I)‐Microdevices for Bioorthogonal Uncaging and Click Reactions
Transition‐metal‐catalyzed bioorthogonal reactions emerged a decade ago as a novel strategy to implement spatiotemporal control over enzymatic functions and pharmacological interventions. The use of this methodology in experimental therapy is driven by the ambition of improving the tolerability and PK properties of clinically‐used therapeutic agents. The preclinical potential of bioorthogonal catalysis has been validated in vitro and in vivo with the in situ generation of a broad range of drugs, including cytotoxic agents, anti‐inflammatory drugs and anxiolytics. In this article, we report our investigations towards the preparation of solid‐supported Cu(I)‐microdevices and their application in bioorthogonal uncaging and click reactions. A range of ligand‐functionalized polymeric devices and off‐on Cu(I)‐sensitive sensors were developed and tested under conditions compatible with life. Last, we present a preliminary exploration of their use for the synthesis of PROTACs through CuAAC assembly of two heterofunctional mating units.
- Open Access
- 11 October 2023
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 14 (12) , 2611-2624
Discovery of pyrazolopyrimidines that selectively inhibit CSF-1R kinase by iterative design, synthesis and screening against glioblastoma cells
Glioblastoma multiforme (GBM) is the most aggressive type of brain cancer in adults, with an average life expectancy under treatment of approx. 15 months. GBM is characterised by a complex set of genetic alterations that results in significant disruption of receptor tyrosine kinase (RTK) signaling. We report here an exploration of the pyrazolo[3,4-d]pyrimidine scaffold in search for antiproliferative compounds directed to GBM treatment. Small compound libraries were synthesised and screened against GBM cells to build up structure–antiproliferative activity–relationships (SAARs) and inform further rounds of design, synthesis and screening. 76 novel compounds were generated through this iterative process that found low micromolar potencies against selected GBM lines, including patient-derived stem cells. Phenomics analysis demonstrated preferential activity against glioma cells of the mesenchymal subtype, whereas kinome screening identified colony stimulating factor-1 receptor (CSF-1R) as the lead's target, a RTK implicated in the tumourigenesis and progression of different cancers and the immunoregulation of the GBM microenvironment.
- 11 October 2023
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 14 (12) , 2611-2624
Open AccessDiscovery of pyrazolopyrimidines that selectively inhibit CSF-1R kinase by iterative design, synthesis and screening against glioblastoma cells
Glioblastoma multiforme (GBM) is the most aggressive type of brain cancer in adults, with an average life expectancy under treatment of approx. 15 months. GBM is characterised by a complex set of genetic alterations that results in significant disruption of receptor tyrosine kinase (RTK) signaling. We report here an exploration of the pyrazolo[3,4-d]pyrimidine scaffold in search for antiproliferative compounds directed to GBM treatment. Small compound libraries were synthesised and screened against GBM cells to build up structure–antiproliferative activity–relationships (SAARs) and inform further rounds of design, synthesis and screening. 76 novel compounds were generated through this iterative process that found low micromolar potencies against selected GBM lines, including patient-derived stem cells. Phenomics analysis demonstrated preferential activity against glioma cells of the mesenchymal subtype, whereas kinome screening identified colony stimulating factor-1 receptor (CSF-1R) as the lead's target, a RTK implicated in the tumourigenesis and progression of different cancers and the immunoregulation of the GBM microenvironment.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Despite the approval of several multikinase inhibitors that target SRC and the overwhelming evidence of the role of SRC in the progression and resistance mechanisms of many solid malignancies, inhibition of its kinase activity has thus far failed to improve patient outcomes. Here we report the small molecule eCF506 locks SRC in its native inactive conformation, thereby inhibiting both enzymatic and scaffolding functions that prevent phosphorylation and complex formation with its partner FAK. This mechanism of action resulted in highly potent and selective pathway inhibition in culture and in vivo. Treatment with eCF506 resulted in increased antitumor efficacy and tolerability in syngeneic murine cancer models, demonstrating significant therapeutic advantages over existing SRC/ABL inhibitors. Therefore, this mode of inhibiting SRC could lead to improved treatment of SRC-associated disorders.Significance:Small molecule–mediated inhibition of SRC impairing both catalytic and scaffolding functions confers increased anticancer properties and tolerability compared with other SRC/ABL inhibitors.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Despite the approval of several multikinase inhibitors that target SRC and the overwhelming evidence of the role of SRC in the progression and resistance mechanisms of many solid malignancies, inhibition of its kinase activity has thus far failed to improve patient outcomes. Here we report the small molecule eCF506 locks SRC in its native inactive conformation, thereby inhibiting both enzymatic and scaffolding functions that prevent phosphorylation and complex formation with its partner FAK. This mechanism of action resulted in highly potent and selective pathway inhibition in culture and in vivo. Treatment with eCF506 resulted in increased antitumor efficacy and tolerability in syngeneic murine cancer models, demonstrating significant therapeutic advantages over existing SRC/ABL inhibitors. Therefore, this mode of inhibiting SRC could lead to improved treatment of SRC-associated disorders.Significance:Small molecule–mediated inhibition of SRC impairing both catalytic and scaffolding functions confers increased anticancer properties and tolerability compared with other SRC/ABL inhibitors.